What is the debt of Mesoblast this year?
Mesoblast has a debt level of 56.36 USD this year.
Mesoblast Debt 2024
Mesoblast Debt
56.36 USD
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2024, Mesoblast's total debt was 56.36 USD, a 20.28% change from the 46.86 USD total debt recorded in the previous year.
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Mesoblast's Debt Structure
Mesoblast's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Mesoblast's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Mesoblast’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Mesoblast’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Mesoblast stock
What was the debt of Mesoblast compared to the previous year?
The debt of Mesoblast has increased by 20.28% compared to the previous year increased.
What are the consequences of high debt for investors in Mesoblast?
High debt can pose a risk for investors of Mesoblast, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Mesoblast?
Low debt means that Mesoblast has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Mesoblast affect the company?
An increase in debt of Mesoblast can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Mesoblast affect the company?
A reduction in debt of Mesoblast can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Mesoblast?
Some factors that can influence the debt of Mesoblast include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Mesoblast so important for investors?
The debts of Mesoblast are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Mesoblast take to change the debt?
To change the debt, Mesoblast can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 9/27/2024.
What was the dividend of Mesoblast in the year 2023?
In the year 2023, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
